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Abstract
Objective—To examine how the time from HIV testing to care referral and from referral to care 
linkage influenced time to care engagement for newly diagnosed HIV-infected adolescents.
Methods—We evaluated the Care Initiative, a care linkage and engagement program for HIV-
infected adolescents in 15 U.S. clinics. We analyzed client-level factors, provider type and 
intervals from HIV testing to care referral and from referral to care linkage as predictors of care 
engagement. Engagement was defined as a second HIV-related medical visit within 16 weeks of 
initial HIV-related medical visit (linkage).
Results—At 32 months, 2,143 youth had been referred. Of these, 866 were linked to care 
through the Care Initiative within 42 days and thus eligible for study inclusion. Of the linked 
youth, 90.8% were ultimately engaged in care. Time from HIV testing to referral (e.g., ≤7 days 
versus >365 days) was associated with engagement (AOR=2.91; 95% CI: 1.43–5.94) and shorter 
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time to engagement (Adjusted HR=1.41; 95% CI: 1.11–1.79). Individuals with shorter care 
referral to linkage intervals (e.g., ≤7 days versus 22–42 days) engaged in care faster (Adjusted 
HR=2.90; 95% CI: 2.34–3.60) and more successfully (AOR=2.01; 95% CI: 1.04–3.89).
Conclusions—These data address a critical piece of the care continuum, and can offer 
suggestions of where and with whom to intervene in order to best achieve the care engagement 
goals outlined in the U.S. National HIV/AIDS Strategy. These results may also inform programs 
and policies that set concrete milestones and strategies for optimal care linkage timing for newly 
diagnosed adolescents.
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INTRODUCTION
The purpose of this paper is to examine factors associated with the time required for 
adolescents to engage in HIV-related care following HIV testing. The development and 
scale-up of youth-focused intensive case management and patient navigation services over 
the past 10 years has markedly improved initial entry into HIV care, although up to 30% of 
adolescents are not promptly linked to care after initial diagnosis1. Moreover, longer-term 
treatment–including anti-retroviral treatment (ART)–rarely begins before the second or 
subsequent visits. The time to ART initiation is critical, since earlier viral suppression 
improves an individual’s HIV health outcomes, and drastically reduces HIV transmission 
risk2–7. Despite its importance in the HIV continuum of care, little information exists to 
identify factors associated with time to engagement that can guide program or service 
planning to achieve these goals, particularly for adolescents. Specifically, there has been 
little focus on modifiable factors that contribute to the interval between HIV testing and care 
engagement.
Engagement refers to the maintenance of HIV-related health care following initial linkage, 
as demonstrated by an individual’s motivation and readiness to attend a second HIV-related 
care appointment within a defined interval after linkage8,9. This is reflected in the HIV 
Medicine Association guidelines that highlight how the “emphasis should be placed on the 
importance of adherence to care rather than focusing solely on adherence to medications”10. 
The interval between HIV testing and engagement in care requires necessarily prior events 
such as a youth’s receipt of positive test results, referral to care, and initial receipt of HIV-
related services (e.g. medical, social, psychological). In contemporary usage, these early 
events in the continuum of care collectively represent care linkage9,11.
Failures in timely care engagement may be especially important for adolescents as this age 
group constitutes 26% of new infections and approximately 60% of HIV-infected 13–24 
year olds are undiagnosed1,12,13. Once diagnosed and linked to care, nearly one-third of 
adolescents drop out of care1,14,15. Adolescents consequently have lower rates of viral 
suppression and higher virologic rebound than adults: Only 6% of adolescents achieve initial 
viral suppression compared to 28% of HIV-infected adults1,14. Engagement is therefore an 
important point in the continuum of care because the full benefits of modern biomedical 
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interventions – prevention of advanced disease, reduced transmission risk, and, reduced 
community viral load – are enacted as part of sustained engagement in care16,17. Little 
research, however, has examined factors that influence the timeliness of engagement in care.
This paper examines social and behavioral factors associated with time to engagement in 
care for newly diagnosed HIV-infected adolescents. These data inform understanding of a 
critical juncture in the HIV care continuum and suggest approaches to achieving the 
National HIV/AIDS Strategy’s goal of “seamless” HIV care from HIV diagnosis to 
sustained viral suppression7.
METHODS
Data were collected from 15 Adolescent Medicine Trials Network (ATN) clinic sites. These 
Adolescent Medicine Trial Units (AMTU) care for adolescents, ages 12–24 years, in 13 
cities across the U.S. and Puerto Rico. The AMTUs are often the primary adolescent-
specific HIV care providers in their respective cities and also offer psychosocial services 
such as mental health, housing, and vocational support. Each AMTU implemented the 
SMILE Program in 2010. This initiative is a collaborative effort of NICHD, CDC, and the 
ATN designed to facilitate linkage to care for adolescents with new HIV infection diagnoses. 
The initiative facilitated formal relationships among the AMTU, health departments, and 
local youth-serving organizations involved with HIV testing and treatment,18 and involved 
development of formal linkage to care protocols, provision of an outreach worker to 
facilitate linkage services and to coordinate referrals within a given catchment area. The 
majority of referrals were assigned to the outreach worker, though some were assigned to 
other AMTU staff or community organizations. SMILE was designed to address the variable 
quality and fragmentation of services characteristic of youth HIV linkage to care activities in 
2010. SMILE also emphasized the importance of formal relationships with the health 
departments intended to improve access to real-time HIV testing data. The criteria for 
referral to SMILE were similar across sites, with variation in referral patterns due to the 
variable success of facilitating linkages between the health department, AMTU, and local 
organizations. Linkage was defined as an HIV-related medical visit within 42 days (i.e., 6 
weeks) of referral; engagement was a second HIV-related medical visit within 16 weeks of 
the initial visit. These definitions reflect the intensive case-management approach adopted 
for the SMILE program, and are more restrictive than standards for care linkage and 
engagement that came into wider use with adult patients after initiation of this study8,19. The 
Institutional Review Board at each site approved all procedures.
Independent measures
Independent measures included client-level factors and provider type. Client-level factors 
included youths’ self-reported age, gender, race/ethnicity, sexual identity, homeless status, 
mode of HIV acquisition, and illicit drug use in the last year (e.g., marijuana and heroin). 
The provider was the person assigned to provide linkage, categorized as the AMTU outreach 
worker, other AMTU staff (e.g., physicians, nurses, case managers), or non-AMTU staff 
(e.g., non-AMTU clinic staff, community-based social worker).
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Outcome measures
We defined two intervals of importance for understanding care engagement. The first 
interval was the time in days between an individual’s first positive HIV test and a second 
HIV-related clinic visit within 16 weeks of the first HIV-related clinic visit (care 
engagement). This diagnosis-engagement interval provides insight into early factors (such as 
difficulty in locating patients for test results or because of inefficient referral networks) that 
could contribute to delays in receiving care. A second interval was time (in days) from 
referral to the SMILE program until a second HIV-related clinic visit within 16 weeks of an 
initial HIV-related clinic. This referral-engagement interval variable provides program 
evaluation data, and can be used to additionally refine standards of care for newly diagnosed 
HIV infected youth. We also examined engagement as a dichotomous outcome, i.e., whether 
an adolescent became engaged in care (or not) within 16 weeks of an initial HIV-related 
visit. This variable serves as a quality of care standard8,19.
Statistical Methods
The proportional hazards regression analysis was used to examine the relationship of time 
from referral to engagement with potential impact factors such as age, gender, race/ethnicity, 
mode of HIV acquisition, client’s housing status, drug use, case assignment status as well as 
time from referral to care linkage, and HIV testing to linkage. For those who engaged in 
care, the time was defined as the days from referral to the engagement (the 2nd medical 
appointment). For those who were not engaged, we used days from referral to either the 2nd 
medical appointment or the summation of lengths of referral to 1st medical appointment and 
half of 16 weeks after the 1st medical appointment. Covariates with an overall p-value of 
0.20 or less were entered into the initial full multivariable model for model selection. The 
stepwise and backward model selection techniques were used to select the best final model. 
A similar analysis was performed for the outcome of time from HIV testing to engagement. 
To determine rates of engagement in care (no/yes), we used logistic regression analysis. All 
data analyses were run in SAS Version 9.3.
RESULTS
Description of Sample
After 32 months, 2,143 youth were referred to the SMILE program. Of these, 344 were 
excluded for having failed earlier linkage to care efforts (n=106), having a prior positive test 
(n=171), and perinatal route of infection (n=67), leaving 1,799 newly diagnosed cases 
referred to the SMILE program. Of these cases, 69.8% were linked to care, of which 89% 
were engaged in care; overall 62.1% of adolescents were linked to care and engaged in care. 
For the analyses in this paper, we additionally eliminated 145/1799 cases because they 
lacked an accurate test date (e.g., missing year, testing date was in the future). Of the 
remaining 1,655 cases, 866 were eligible for engagement in care because they completed an 
initial linkage to care visit within 42 days of referral.
The study sample was predominantly male (80%), black (77%), and had acquired HIV 
through male-to-male sexual contact (74%). The mean age was 20.7 years, 66% reported 
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drug use in the last year and most (80%) were assigned to an AMTU outreach worker (Table 
1).
Time from HIV testing to engagement in care—The unadjusted Cox Model for time 
from HIV testing to engagement in care (Table 2) demonstrates that individuals who were 
referred and linked more quickly had a higher likelihood of care engagement, as did younger 
individuals, males, people who acquired HIV through male-to-male sexual contact, and 
individuals assigned to other AMTU staff. Specifically, individuals who were referred to 
care within 365 days of being HIV tested had higher rates of care engagement than those 
who were referred after 365 days, though which a much greater effect size in the first 28 
days compared to the rest of the first year. Individuals with shorter time intervals from 
referral to linkage were more likely to engage in care (HR =1.36. 95% CI: 1.11–1.66). 
Younger individuals also had a higher likelihood of engagement as did males (HR=1.38; 
95% CI: 1.13–1.67) versus females, HIV acquisition by male-to-male sexual contact 
(HR=1.24; 95% CI: 1.04–1.48) versus different sex contact, and those who were assigned to 
other AMTU staff (HR=1.51; 95% CI: 1.21–1.87) compared to an AMTU outreach worker. 
Ethnicity other than non-Hispanic white was associated with a lower likelihood of 
engagement.
The adjusted Cox model showed that individuals with shorter intervals for referral and 
linkage to care were more likely to engage in care, as were non-white clients and those 
assigned to other AMTU staff. Shorter intervals from HIV testing to referral (under 365 days 
compared to >365 days) were much more likely to be engaged in care, though there is a 
decreasing magnitude of the trend as time from testing to referral lengthens. Individuals with 
shorter length from referral to linkage to care (under 21 days compared to 22–42 days) also 
had greater likelihood of care engagement. Referral and linkage on the same day was not 
associated with engagement (Table 2). Compared to non-Hispanic white individuals, non-
Hispanic blacks, non-Hispanic others, and Hispanics were less likely to be engaged in care. 
Clients who were assigned to other AMTU staff compared to an outreach worker (HR=1.29; 
95% CI: 1.02–1.62) were more likely to have shorter engagement in care intervals.
Time from referral to engagement in care—Factors related to interval from SMILE 
program referral to engagement in the unadjusted model also included clients who used 
drugs in the last 12 months (Table 3). Individuals referred to the SMILE program within 28 
days of testing had a higher likelihood of being engaged in care than those referred after one 
year. Similarly, individuals linked to care on the same day as referral and within 21 days of 
referral had a higher likelihood of engagement in care than those linked 22–42 days after 
referral. Clients who used drugs in the past 12 months (HR=1.19; 95% CI: 1.02–1.39) and 
individuals assigned to other AMTU staff (HR=1.27; 95% CI: 1.03–1.58) compared to 
AMTU outreach workers were more likely to engage. Hispanics were less likely to be 
engaged in care (HR=0.57; 95% CI: 0.41–0.81) compared to Non-Hispanic Whites.
The results from the adjusted Cox model indicate that time from referral to linkage to care, 
time from HIV testing to referral, race/ethnicity, and mode of HIV acquisition were 
associated with engagement in care (Table 3). Subjects with a shorter time from HIV testing 
to referral (i.e., <28 days compared to >365 days) had an approximate 41% to 69% 
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increased likelihood of shorter time to care engagement. The length from referral to linkage 
to care showed that individuals linked more quickly (i.e. in the first three weeks) were also 
more likely to engage in care than those linked within 22–42 days. Compared to non-
Hispanic whites, Non-Hispanic Blacks, Non-Hispanic Other, and Hispanics were less likely 
to be engaged in care. Individuals who reported acquiring HIV through male-to-male sexual 
contact had a shorter time to engagement in care than those who acquired HIV through 
heterosexual contact.
Factors associated with rates of engagement in care (see Table 4)—Adolescents 
with a shorter time from HIV testing to referral (0–7, 8–14, and 15–28 days versus >365 
days) were more likely to engage in care as were those with shorter time in days from 
referral to linkage to care (1–7 and 8–14 days versus 22–42 days). Individuals who self-
identified as non-Hispanic and those assigned to non-AMTU staff compared to the linkage 
to care outreach worker were less likely to engage in care20.
DISCUSSION
This study demonstrates that the time interval between a newly diagnosed adolescent’s HIV 
test and care referral and the time interval between care referral and first medical visit 
(linkage to care) have concrete implications for long-term HIV-care engagement. 
Specifically, the results show that the speed with which an adolescent is initially 
incorporated into the network of care services matters for engagement. Those that have 
shorter intervals between HIV test and referral, and referral to linkage, are more likely to 
quickly engage in care, and more successfully.
These findings suggest that care engagement is the outcome of a process that begins very 
early in the HIV care continuum, and may be influenced by factors other than support for 
adherence to HIV clinic appointments21. These data have quality of care implications for 
HIV testing programs in that the speed with which HIV-positive youth are referred for 
linkage has downstream implications for engagement – a step in the HIV Care Continuum 
that is critical for initiation of ART and other prevention services9. The data also support the 
importance in early, active patient engagement to reduce drop-out from care after initial 
linkage to care22,23.
Our data also suggest that HIV care is truly a continuum, so that earlier outcomes may be 
important throughout the post-test period, not just through effects on the next immediate 
continuum milestone. Even if a youth does not immediately link, early referral and 
connection to clinic staff can help support eventual engagement24. The findings also 
highlight which youth (i.e., women, non-white youth, youth who acquired HIV through 
heterosexual sex) need additional support to be more quickly referred, linked, and eventually 
engaged in care. It also highlights the importance of where and to whom a youth is assigned 
to care. These data show that individuals who were assigned to AMTU staff were more 
likely to engage, yet those assigned to other AMTU staff (compared to the outreach worker) 
had shorter engagement intervals. Outreach workers were often assigned the youth with 
most challenging barriers, which often impacted time to linkage and engagement. This 
highlights the variation in needs of individual youth and the importance of clinical 
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infrastructure with capacity to provide clinical care and wraparound services by staff 
dedicated to the linkage process.
These findings are particularly meaningful because the HIV care continuum often depicts 
progress from HIV testing to care linkage and engagement as one step;9,11 little attention has 
been given to the role of referral to care. Specifically, we found no research examining the 
length of the interval from HIV testing to referral, referral to linkage, or HIV testing to 
linkage and implications for care engagement with an ultimate goal of viral suppression. 
Irrespective of the strength of a care linkage system, an individual has to be tested and 
referred to care. These results demonstrate the important role timing plays in that initial step, 
suggesting the need for both a care linkage infrastructure and close collaborations between 
community-based organizations that provide testing, health departments, and adolescent 
medicine clinics18. Previous research25,26 has demonstrated how community mobilization 
can improve community networks, which in turn facilitate the pathways through which HIV 
testing occurs and referrals to linkage are made. This is particularly true as calls to ‘test and 
treat’ expand and cause HIV testing to occur in more diverse venues, many of which may 
not have as much experience referring and linking individuals into care. The diversity of 
testing locations will also become more salient as testing expands into lower prevalence 
areas that may not have strong referral networks. Given that individuals tested in community 
venues take longer to refer and link to care,27 our work shows it is imperative to create an 
organized public health approach to facilitate individuals’ pathway through the gaps in the 
care continuum between “test” and “treat” to improve engagement, and ultimately, viral 
suppression outcomes among HIV-infected youth.
The study found that the referral and linkage infrastructure seems to work more successfully 
for certain populations of youth, while others take longer to link and engage and will require 
more resources to ensure that they do. Such discrepancies may exist given the demographics 
of the US HIV/AIDS epidemic. For example, clinics may tailor their services to MSM, 
making females or heterosexual men feel less welcome or less comfortable24. Adolescent in 
particular may also feel that accessing care does not outweigh the social risk of inadvertent 
disclosure or stigma. Such individuals should be the focus of future interventions to facilitate 
successful engagement for all youth.
Providers described adolescents as frequently unwilling to accept their diagnoses or the level 
of clinical engagement their diagnosis would require. In such instances, providers advocated 
for other strategies (and the provision of wraparound services) to increase chances of 
eventual engagement. Many newly diagnosed adolescents refused to disclose to anybody due 
to a lack of family or community support; system fragmentation also compromises rapid 
linkage to care28–30. However, such findings are complicated by these data that demonstrate 
the need to refer and link youth as quickly as possible. Being able to expedite the referral 
and linkage process for adolescents requires testing staff and providers with youth-focused 
skills and a network of clinics and community organizations that can assist them24. Studies 
have shown the individual and community-level implications of delayed care linkage; the 
relationship between rapid linkage and poorer engagement is likely due to adolescents still 
adjusting to their diagnoses, being overwhelmed by the amount of medical information and 
thus unsure of how to proceed, or insecurities in engaging with medical providers20,21,24. 
Philbin et al. Page 7
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
This study demonstrates that the definition of care linkage as one visit within a period of 
time may be insufficient to help an adolescent stay on the care continuum and ultimately 
become engaged in care. More specifically, care linkage is not a single event that involves 
only a medical visit and a blood draw. Instead, it should be treated as part of a larger process 
that requires multiple medical and non-medical visits, phone calls, emails, and/or texts, even 
for those who are linked on the first day. It is important to refer and link each individual to 
care as quickly as possible after testing to increase the speed and likelihood of engagement, 
ART prescription, and ultimate health outcomes.
Limitations
Our study represents a large and comprehensive data set for care linkage and engagement for 
HIV-infected adolescents. HIV testing within communities, however, is neither systematic 
nor coordinated with mandated reporting. Such disjunctures often delayed a provider’s 
ability to refer for care linkage by several months, and referral systems vary across the 15 
ATN clinics. Referral bias is also possible: a small proportion (about 16%) of youth were 
already linked to care at the time of referral; these individuals were excluded from analysis. 
There were individuals who were not linked to care within 42 days and then re-entered into 
the database and linked to care during a second 42-day period; these individuals were 
duplicates and thus also excluded from the analyses. The ATN sites are all located in major 
urban metropolitan centers where the HIV epidemic is concentrated for youth and may not 
be generalizable to other settings in the US.
Conclusion
This research demonstrated that only 62% of newly diagnosed HIV-positive adolescents are 
linked and engaged in care within 22 weeks of referral, and thus identify an additional point 
in the HIV care continuum that needs to be examined—the time between HIV testing and 
referral and referral and linkage—as predictive of care engagement. Indeed, this gap in the 
care continuum must be addressed in order for the US to successfully address the HIV 
epidemic. Our research suggests that each newly diagnosed HIV-infected youth needs to be 
linked to care as quickly as possible in order to facilitate a more rapid engagement in care, 
access to medications, and better long term prognosis. Intensive linkage-focused 
interventions could increase rapid engagement and thus medication initiation and viral 
suppression. This focus on rapid linkage, however, should also incorporate an assessment of 
whether an adolescent is actually ready to participate in care. Our results highlight ways to 
approach care for newly diagnosed adolescents that may facilitate improvements in how 
youth initiate a lifetime of care. The processes through which a newly diagnosed HIV-
infected adolescent is identified, referred, linked, and engaged in care is often complex and 
requires coordination between health departments, community organizations, and national-
level policy making. Accordingly, these data should be used to build evidence and help 
construct a seamless continuum of care for HIV-infected youth to help fulfill the goals 
outlined in the U.S. National HIV/AIDS Strategy.
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Table 1
Demographic Characteristics among All 866 HIV-Positive Adolescents
n (%)(N=866) Mean (std. dev.) Median (min.-max.)
Age (years)- continuous 20.68 (2.22) 21 (13 – 24)
   12 – 17 83 (9.63)
   18 – 20 301 (34.92)
   21 – 22 283 (32.83)
   23 – 24 195 (22.62)
   Missing 4
Gender
   Male 695 (80.35)
   Female 148 (17.11)
   Transgender 22 (2.54)
   Missing 1
Race
   White 87 (10.13)
   Black 660 (76.83)
   American Indian/Alaskan Native 2 (0.23)
   Asian 1 (0.12)
   Mixed Race 70 (8.15)
   Other 29 (3.38)
   Not asked/Refused to answer 10 (1.16)
Ethnicity
   Hispanic 133 (15.48)
   Non-Hispanic 726 (84.52)
   Missing 7
Race/Ethnicity
   Non-Hispanic White 52 (6.08)
   Non-Hispanic Black 635 (74.27)
   Non-Hispanic Other 35 (4.09)
   Hispanic 133 (15.56)
   Missing 11
Mode of Acquisition
   Heterosexual contact 184 (21.27)
   Male to male sexual contact 641 (74.10)
   IDU + Other 40 (4.62)
   Missing 1
Time Between HIV Test Date and referral to Care Initiative (days) 178.30 (434.30) 17 (0 – 4089)
   0–7 286 (34.38)
   8 – 14 105 (12.62)
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n (%)(N=866) Mean (std. dev.) Median (min.-max.)
   15 – 28 104 (12.50)
   29 – 42 63 (7.57)
   43 – 60 49 (5.89)
   61 – 120 57 (6.85)
   121 – 180 20 (2.40)
   181 – 365 35 (4.21)
   365+ 113 (13.58)
   Missing 34
What is the client’s current housing status: homelessness
   Yes 15 (1.97)
   No 745 (98.03)
   Not assessed (unknown)/Other/Refuse to answer/Missing 106
Has the client used any of the drugs in the past 12 months?
   Yes 572 (66.05)
   No 294 (33.95)
Case Assignment
   LTC OW 689 (79.65)
   Other AMTU staff 111 (12.83)
   Non-AMTU staff 65 (7.51)
Engaged in care
   Yes 786 (90.76)
   No 80 (9.24)
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Philbin et al. Page 13
Ta
bl
e 
2
R
el
at
io
ns
hi
p 
of
 T
im
e 
fro
m
 H
IV
 T
es
tin
g 
to
 E
ng
ag
em
en
t-i
n-
Ca
re
 w
ith
 P
ot
en
tia
l I
m
pa
ct
 F
ac
to
rs
 (C
ox
 M
od
el)
To
ta
l
n
 (%
)
EI
C
n
 (%
)
N
o 
EI
C
n
 (%
)
H
R
*
 
(95
%
 C
I)
p-
va
lu
e
A
dju
ste
d H
R
(95
%
 C
I*
)
p-
va
lu
e
D
ay
s f
ro
m
 H
IV
 te
sti
ng
 to
 re
fe
rra
l
 
 
 
0–
7
28
6 
(34
.38
)
26
5 
(92
.66
)
21
 (7
.34
)
12
3.
44
 (7
5.3
4 –
20
2.2
4)
<
0.
00
01
15
5.
19
 (9
2.7
1 –
25
9.7
6)
<
0.
00
01
 
 
 
8 
– 
14
10
5 
(12
.62
)
99
 (9
4.2
9)
6 
(5.
71
)
12
6.
13
 (7
4.1
2 –
21
4.6
3)
<
0.
00
01
14
9.
15
 (8
6.0
1 –
25
8.6
4)
<
0.
00
01
 
 
 
15
 –
 2
8
10
4 
(12
.50
)
98
 (9
4.2
3)
6 
(5.
77
)
91
.1
7 
(53
.64
 –1
54
.96
)
<
0.
00
01
11
7.
68
 (6
7.7
0 –
20
4.5
7)
<
0.
00
01
 
 
 
29
 –
 3
65
22
4 
(26
.92
)
20
1 
(89
.73
)
23
 (1
0.2
7)
25
.9
5 
(15
.80
 –4
2.6
3)
<
0.
00
01
28
.6
6 
(17
.13
 –4
7.9
5)
<
0.
00
01
 
 
 
36
5+
11
3 
(13
.58
)
94
 (8
3.1
9)
19
 (1
6.8
1)
1.
00
1.
00
D
ay
s f
ro
m
 re
fe
rra
l t
o 
LT
C
 
 
 
0 
da
y
11
4 
(13
.21
)
10
3 
(90
.35
)
11
 (9
.65
)
0.
84
 (0
.66
 –1
.09
)
0.
19
00
1.
21
 (0
.92
 – 
1.5
8)
0.
17
27
 
 
 
1–
7
26
3 
(30
.48
)
24
2 
(92
.02
)
21
 (7
.98
)
1.
36
 (1
.11
 –1
.66
)
0.
00
30
2.
06
 (1
.67
 –2
.54
)
<
0.
00
01
 
 
 
8–
14
18
9 
(21
.90
)
17
6 
(93
.12
)
13
 (6
.88
)
1.
45
 (1
.17
 –1
.80
)
0.
00
07
1.
82
 (1
.45
 –2
.27
)
<
0.
00
01
 
 
 
15
–2
1
10
7 
(12
.40
)
97
 (9
0.6
5)
10
 (9
.35
)
1.
25
 (0
.96
 –1
.61
)
0.
09
26
1.
41
 (1
.09
 –1
.84
)
0.
00
97
 
 
 
22
–4
2
19
0 
(22
.02
)
16
5 
(86
.84
)
25
 (1
3.1
6)
1.
00
1.
00
A
ge
 (y
ea
rs)
 
 
 
12
 –
 1
7
83
 (9
.63
)
81
 (9
7.5
9)
2 
(2.
41
)
2.
05
 (1
.56
 –2
.70
)
<
0.
00
01
 
 
 
18
 –
 2
0
30
1 
(34
.92
)
27
7 
(92
.03
)
24
 (7
.97
)
1.
76
 (1
.44
 –2
.15
)
<
0.
00
01
 
 
 
21
 –
 2
2
28
3 
(32
.83
)
25
5 
(90
.10
)
28
 (9
.90
)
1.
33
 (1
.09
 –1
.63
)
0.
00
48
 
 
 
23
 –
 2
4
19
5 
(22
.62
)
17
1 
(87
.69
)
24
 (1
2.3
1)
1.
00
G
en
de
r
 
 
 
M
al
e
69
5 
(80
.35
)
62
7 
(90
.22
)
68
 (9
.78
)
1.
38
 (1
.13
 –1
.67
)
0.
00
12
 
 
 
Fe
m
al
e
14
8 
(17
.11
)
13
9 
(93
.92
)
9 
(6.
08
)
1.
00
 
 
 
Tr
an
sg
en
de
r
22
 (2
.54
)
20
 (9
0.9
0)
2 
(9.
10
)
0.
89
 (0
.55
 –1
.43
)
0.
62
08
R
ac
e/
Et
hn
ic
ity
 
 
 
N
on
-H
isp
an
ic
 W
hi
te
52
 (6
.08
)
50
 (9
6.1
5)
2 
(3.
85
)
1.
00
1.
00
 
 
 
N
on
-H
isp
an
ic
 B
la
ck
63
5 
(74
.27
)
58
0 
(91
.34
)
55
 (8
.66
)
0.
79
 (0
.59
 –1
.06
)
0.
11
56
0.
52
 (0
.38
 –0
.70
)
<
0.
00
01
 
 
 
N
on
-H
isp
an
ic
 O
th
er
35
 (4
.09
)
29
 (8
2.8
6)
6 
(17
.14
)
0.
54
 (0
.34
 –0
.86
)
0.
00
87
0.
42
 (0
.26
 –0
.68
)
0.
00
04
 
 
 
H
isp
an
ic
13
3 
(15
.56
)
11
9 
(89
.47
)
14
 (1
0.5
3)
0.
79
 (0
.57
 –1
.11
)
0.
17
97
0.
48
 (0
.34
 –0
.68
)
<
0.
00
01
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Philbin et al. Page 14
To
ta
l
n
 (%
)
EI
C
n
 (%
)
N
o 
EI
C
n
 (%
)
H
R
*
 
(95
%
 C
I)
p-
va
lu
e
A
dju
ste
d H
R
(95
%
 C
I*
)
p-
va
lu
e
M
od
e 
of
 A
cq
ui
sit
io
n
 
 
 
H
et
er
os
ex
u
al
 c
on
ta
ct
18
4 
(21
.27
)
17
1 
(92
.93
)
13
 (7
.07
)
1.
00
 
 
 
M
al
e 
to
 m
al
e 
se
x
u
al
 c
on
ta
ct
64
1 
(74
.10
)
58
2 
(90
.80
)
59
 (9
.20
)
1.
24
 (1
.04
 –1
.48
)
0.
01
54
 
 
 
ID
U
 +
 O
th
er
40
 (4
.62
)
32
 (8
0.0
0)
8 
(20
.00
)
1.
12
 (0
.76
 –1
.64
)
0.
57
31
W
ha
t i
s t
he
 c
lie
nt
’s
 c
ur
re
nt
 h
ou
sin
g 
sta
tu
s: 
ho
m
el
es
sn
es
s
 
 
 
Ye
s
15
 (1
.97
)
14
 (9
3.3
3)
1 
(6.
77
)
0.
83
 (0
.49
 –1
.41
)
0.
48
06
 
 
 
N
o
74
5 
(98
.03
)
68
3 
(91
.68
)
62
 (8
.32
)
1.
00
H
as
 th
e 
cl
ie
nt
 u
se
d 
an
y 
of
 th
e 
dr
ug
s i
n 
th
e 
pa
st 
12
 m
on
th
s?
 
 
 
Ye
s
57
2 
(66
.05
)
52
2 
(91
.26
)
50
 (8
.74
)
1.
09
 (0
.94
 –1
.27
)
0.
26
15
 
 
 
N
o
29
4 
(33
.95
)
26
4 
(89
.80
)
30
 (1
0.2
0)
1.
00
Ca
se
 A
ss
ig
nm
en
t
 
 
 
LT
C 
OW
68
9 
(79
.65
)
63
1 
(91
.58
)
58
 (8
.62
)
1.
00
1.
00
 
 
 
O
th
er
 A
M
TU
 st
af
f
11
1 
(12
.83
)
10
1 
(90
.99
)
10
 (9
.01
)
1.
51
 (1
.21
 –1
.87
)
0.
00
02
1.
29
 (1
.02
 –1
.62
)
0.
03
20
 
 
 
N
on
-A
M
TU
 st
af
f
65
 (7
.51
)
53
 (8
1.5
4)
12
 (1
8.6
6)
1.
05
 (0
.79
 –1
.39
)
0.
73
81
0.
92
 (0
.68
 –1
.24
)
0.
58
08
*
H
R
: h
az
ar
d 
ra
tio
; C
I: 
co
nf
id
en
ce
 in
te
rv
al
.
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Philbin et al. Page 15
Table 3
Relationship of Time from Referral to Engagement-in-Care with Potential Impact Factors (Cox Model)
HR (95% CI) p-value Adjusted HR(95% CI)
p-value
Days from HIV testing to referral
   0–7 1.41 (1.11 –1.79) 0.0048 1.41 (1.11 –1.80) 0.0056
   8 – 14 1.69 (1.27 –2.26) 0.0003 1.66 (1.24 –2.22) 0.0007
   15 – 28 1.49 (1.11 –1.98) 0.0069 1.68 (1.24 –2.26) 0.0007
   29 – 365 1.10 (0.85 –1.41) 0.4681 1.12 (0.87 –1.45) 0.3820
   365+ 1.00 1.00
Days from referral to LTC
   0 day 1.58 (1.23 –2.04) 0.0004 1.77 (1.36 –2.30) <0.0001
   1-7 2.53 (2.06 –3.11) <0.0001 2.90 (2.34 –3.60) <0.0001
   8-14 2.03 (1.63 –2.52) <0.0001 2.17 (1.73 –2.72) <0.0001
   15-21 1.61 (1.24 –2.08) 0.0003 1.64 (1.26 –2.14) 0.0003
   22-42 1.00 1.00
Age (years)
   12 – 17 1.21 (0.93 –1.59) 0.1607
   18 – 20 1.12 (0.92 –1.36) 0.2500
   21 – 22 0.93 (0.76 –1.13) 0.4531
   23 – 24 1.00
Gender
   Male 1.17 (0.97 –1.41) 0.1018
   Female 1.00
   Transgender 0.98 (0.61 –1.57) 0.9264
Race/Ethnicity
   Non-Hispanic White 1.00 1.00
   Non-Hispanic Black 0.73 (0.54 –0.98) 0.0364 0.56 (0.42 –0.77) 0.0003
   Non-Hispanic Other 0.58 (0.36 –0.92) 0.0210 0.45 (0.28 –0.73) 0.0011
   Hispanic 0.57 (0.41 –0.81) 0.0013 0.44 (0.31–-0.62) <0.0001
Mode of Acquisition
   Heterosexual contact 1.00 1.00
   Male to male sexual contact 1.15 (0.97 –1.37) 0.1153 1.27 (1.06 –1.52) 0.0099
   IDU + Other 0.82 (0.56 –1.20) 0.2967 1.03 (0.69 –1.55) 0.8698
What is the client’s current housing status: homelessness
   Yes 1.31 (0.76 –2.25) 0.3290
   No 1.00
Has the client used any of the drugs in the past 12 months?
   Yes 1.19 (1.02 –1.39) 0.0229
   No 1.00
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HR (95% CI) p-value Adjusted HR(95% CI)
p-value
Case Assignment
   LTC OW 1.00
   Other AMTU staff 1.27 (1.03 –1.58) 0.0278
   Non-AMTU staff 1.02 (0.76 –1.36) 0.8960
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Table 4
Adjusted Relationship of Time in Days from Referral to Engagement-in-Care with Potential Impact Factors
AOR* (95% CI) p-value
Days from HIV testing to referral
   0–7 2.91 (1.43 –5.94) 0.0033
   8 – 14 3.37 (1.25 –9.07) 0.0164
   15 – 28 3.61 (1.33 –9.80) 0.0115
   29 – 365 1.86 (0.92 –3.74) 0.0834
   365+ 1.00
Days from referral to LTC
   0 day 2.29 (0.98 –5.37) 0.0571
   1–7 2.01 (1.04 –3.89) 0.0382
   8–14 2.43 (1.13 –5.27) 0.0238
   15–21 1.32 (0.59 –2.95) 0.4926
   22–42 1.00
Race/Ethnicity
   Non-Hispanic White 1.00
   Non-Hispanic Black 0.42 (0.10 –1.82) 0.2488
   Non-Hispanic Other 0.17 (0.03 –0.92) 0.0400
   Hispanic 0.34 (0.07 –1.59) 0.1701
Case Assignment
   LTC OW 1.00
   Other AMTU staff 0.75 (0.35 –1.62) 0.4674
   Non-AMTU staff 0.32 (0.15 –0.70) 0.0044
*AOR: Adjusted odds ratio; CI: confidence interval.
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